Kinnate BioPharma

Biotechnology

Ticker

KNTE.NASDAQ

Trh

Rok založení

2018

Uzávěrka

12/20/2020

Datum IPO

12/2/2020

Cena umístění

$20

Ziskovost

87.95%

O společnosti

Total Funding

$194.5M

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations.

The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Number of employees

51-100

Headquarters

San Diego, California, United States